John Maddox, MD
Family Medicine · Andalusia, ALNPI 1477575868
Payments from drug & device makers
Across 180 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$978
- AstraZeneca$592
- AbbVie$278
- Bayer$270
- Pfizer$232
- Lilly USA, LLC$227
- plus $1K from 19 others
What the payments were for
- Travel & lodging$251%
- Food & beverage$3,59799%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 43 | $978 |
| AstraZeneca | 27 | $592 |
| AbbVie(2 entities) | 16 | $278 |
| Bayer | 11 | $270 |
| Pfizer | 16 | $232 |
| Lilly USA, LLC | 13 | $227 |
| Esperion Therapeutics, Inc. | 5 | $201 |
| Dexcom, Inc. | 7 | $119 |
| Otsuka America Pharmaceutical, Inc. | 6 | $114 |
| GSK | 5 | $94 |
| Abbott | 5 | $87 |
| Biohaven Pharmaceuticals, Inc. | 6 | $84 |
| Nevro Corp. | 3 | $47 |
| Amarin Pharma, Inc. | 2 | $43 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Merck | 2 | $26 |
| Globus Medical | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Exact Sciences | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Johnson & Johnson | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,622 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 283 | $152,844 |
| JardianceEmpagliflozin | 74 | $68,144 |
| TrulicityDulaglutide | 52 | $65,679 |
| FarxigaDapagliflozin Propanediol | 62 | $63,165 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $57,805 |
| XareltoRivaroxaban | 57 | $35,984 |
| OzempicSemaglutide | 37 | $35,436 |
| EntrestoSacubitril/Valsartan | 40 | $28,572 |
| MounjaroTirzepatide | 24 | $24,960 |
| MyrbetriqMirabegron | 33 | $18,957 |
| NexletolBempedoic Acid | 25 | $15,594 |
| JanuviaSitagliptin Phosphate | 17 | $14,945 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $13,804 |
| BrilintaTicagrelor | 20 | $12,751 |
| Gabapentin | 568 | $12,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $232 | $157,556298 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin N | $227 | $95,126103 claims |
| AstraZenecaFarxiga, Brilinta | $592 | $75,91682 claims |
| GSKTrelegy Ellipta | $94 | $57,80575 claims |
| Novo NordiskOzempic, Rybelsus | $978 | $46,69248 claims |
| Johnson & JohnsonXarelto | $15 | $35,98457 claims |
| Esperion Therapeutics, Inc.Nexletol | $201 | $15,59425 claims |
| MerckJanuvia | $26 | $14,94517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Andalusia
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.